Objective To evaluate the short-term relief and long-term control of acute moderate asthma in adult patients by atorvastatin. Methods A total of 80 adult patients with acute moderate asthma were randomly divided into treatment and control groups, 40 cases in each. Both groups were administrated with fluticasone/salmeterol composite dry powder inhaler at the dose of 250 μg/50 μg twice a day in the acute phase and once daily in remission. The treatment group was also given 40 mg atorvastatin for the first day, followed by 20 mg daily for long term maintenance. We observed asthma symptoms, wheezing disappearance, length of hospital stay, forced expiratory volume in the first second ( FEV1) , peak expiratory flow (PEF) , asthma control level within the following 3 months as well as adverse events in the two experimental groups. Results The duration of asthma remission, wheezing disappearance, and length of hospital stay (4.60±0. 18,5.28±0. 18,and 7. 50±0. 20 d, respectively) in the treatment group were shorter than those (5. 52±0. 20,6. 45±0. 23,and 8. 63±0. 20 d, respectively) in the control group (P<0.01). The experimental group had significantly better improvements of FEV1 (0. 312±0.076 vs. 0.276±0.069 L, P<0.05) and PEF (52. 6±10. 8 vs. 42.6±11.5 mL · min-1 , P<0. 01) as compared to the control group. Asthma control within 3 months in the experimental group was better than that of the control group(92. 5% vs. 70. 0% ,P<0.05). The two groups presented similar safety profile. Conclusion Astorvastatin is safe and effective for relieving symptoms of acute phase and the providing long term management of the disease in adult patients with asthma.%目的 评价阿托伐他汀对成年哮喘急性发作短期症状缓解及长期控制水平的影响.方法 哮喘急性发作的患者80例,随机分为治疗组和对照组各40例,两组急性期均予氟替卡松/沙美特罗复合干粉吸入剂250/50 μg,每次1吸,bid；缓解期均给予氟替卡松/沙美特罗复合干粉吸入剂,每次1吸,qd,维持；治疗组在此基础上加服阿托伐他汀,首日40 mg,随后20 mg·d-1长期维持.观察两组气喘缓解、哮鸣音消失、住院时间,第一秒钟用力呼气容积(FEV1)、最大呼气流量(PEF)改善情况,3个月内哮喘控制水平,并比较两组不良反应.结果 治疗组气喘缓解、哮鸣音消失、住院时间[分别为(4.60±0.18),(5.28±0.18),(7.50±0.20)d]均短于对照组[分别为(5.52±0.20),(6.45±0.23),(8.63±0.20)d,均P＜0.01]；FEV1、PEF[分别为(0.312±0.076)L,(52.6±10.8) mL·min-1]的改善均优于对照组[分别为(0.276±0.069)L,(42.6±11.5) mL·min-1,P＜0.05或P＜0.01],3个月内哮喘控制水平(92.5％)好于对照组(70.0％,P＜0.05),两组用药安全性相似.结论 阿托伐他汀可以安全用于成年哮喘患者,有助于迅速缓解急性期症状,并有益于哮喘的长期管理.
展开▼
